^
    Back
    Association details:
    Biomarker:IDO1 expression
    Cancer:Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

    Excerpt:
    ...Evaluate preoperative clinical/radiologic response rate`Assess progression free survival`Assess overall survival`Assess biomarkers CD8 T cell, PD-L1 and IDO expression by immunohistochemistry`Assess safety and adverse events...
    Trial ID:
    NCT02736123
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SITC 2019
    Title:

    Identification of mRNA signatures that predict response to immunotherapy in melanoma patients

    Published date:
    11/08/2019
    Excerpt:
    Among other genes, IDO1 mRNA was also found to be significantly associated with longer PFS (P < 0.01, False discovery rate (FDR) = 0.18) and OS (P < 0.01, FDR = 0.052).